Effect of Tadalafil on Male Lower Urinary Tract Symptoms: An Integrated Analysis of Storage and Voiding International Prostate Symptom Subscores from Four Randomised Controlled Trials

被引:27
作者
Chapple, Christopher R. [1 ]
Roehrborn, Claus G. [2 ]
McVary, Kevin [3 ]
Ilo, Dapo [4 ]
Henneges, Carsten [5 ]
Viktrup, Lars [6 ]
机构
[1] Sheffield Hallam Univ, Sheffield Teaching Hosp NHS Fdn Trust, Dept Urol, Sheffield S1 1WB, S Yorkshire, England
[2] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[3] So Illinois Univ, Sch Med, Div Urol, Springfield, IL USA
[4] Lilly UK, Basingstoke, Hants, England
[5] Lilly Deutschland, Bad Homburg, Germany
[6] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
Benign prostatic hyperplasia; International prostate symptom score; Lower urinary tract symptoms; Storage; Tadalafil; Voiding; HYPERPLASIA IMPACT INDEX; QUALITY-OF-LIFE; DOUBLE-BLIND; DIAGNOSTIC-VALUE; HEALTH-STATUS; PLACEBO; MEN; TAMSULOSIN; EFFICACY; SILODOSIN;
D O I
10.1016/j.eururo.2014.08.072
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The international prostate symptom score (IPSS) evaluates lower urinary tract symptoms (LUTS) in men with suspected benign prostatic hyperplasia (BPH); the total score does not differentiate between storage and voiding and is unevenly weighted (four questions [57%] on voiding, three questions [43%] on storage). Objective: To evaluate the relative contributions of storage and voiding IPSS subscores to total IPSS at baseline and in response to treatment with tadalafil. Design, setting, and participants: Integrated analysis of data from four placebo-controlled, 12-wk studies of tadalafil (5 mg once daily) in 1499 men with LUTS/BPH. Outcome measurements and statistical analysis: Relationships between total IPSS and the storage and voiding subscores were assessed using graphical exploration and linear regression modelling. Linear modelling was performed for the baseline and endpoint and for changes in subscores. The optimal storage subscore to total IPSS (S:T) ratio for IPSS improvement was identified using nonparametric regression and gradient-descent optimisation. Results and limitations: The contribution of storage and voiding subscores at baseline and endpoint was 38.8% and 61.2%, and 39.2% and 60.7%, respectively. This intuitive 40:60 storage-to-voiding ratio was similar at baseline and endpoint by treatment group and for changes insubscores, but spanned the entire range for individuals. Changes in total IPSS were greatest for a storage subscore percentage contribution to total IPSS of 42.7%. There was no statistical association between S:T ratio (>= 40% vs <40%) at baseline and response to tadalafil. The main limitation was the use of unvalidated storage and voiding IPSS subscores. Conclusions: A constant S:T ratio of 4:10 was observed at baseline and endpoint. The greatest effect on total IPSS was noted for an S:T percentage contribution of 42.7%. Tadalafil efficacy was unaffected by the level of storage dysfunction at baseline. Patient summary: This analysis shows that for men with BPH, improvements during treatment with tadalafil apply to both storage and voiding symptoms at a constant ratio. The extent of storage dysfunction before treatment did not affect the response to treatment. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:114 / 122
页数:9
相关论文
共 38 条
[1]   Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action [J].
Andersson, Karl-Erik ;
de Groat, William C. ;
McVary, Kevin T. ;
Lue, Tom F. ;
Maggi, Mario ;
Roehrborn, Claus G. ;
Wyndaele, Jean Jacques ;
Melby, Thomas ;
Viktrup, Lars .
NEUROUROLOGY AND URODYNAMICS, 2011, 30 (03) :292-301
[2]  
BARRY MJ, 1995, MED CARE, V33, pAS145
[3]   BENIGN PROSTATIC HYPERPLASIA SPECIFIC HEALTH-STATUS MEASURES IN CLINICAL RESEARCH - HOW MUCH CHANGE IN THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AND THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX IS PERCEPTIBLE TO PATIENTS [J].
BARRY, MJ ;
WILLIFORD, WO ;
CHANG, YC ;
MACHI, M ;
JONES, KM ;
WALKERCORKERY, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1995, 154 (05) :1770-1774
[5]   Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-Blockers [J].
Chapple, Christopher ;
Herschorn, Sender ;
Abrams, Paul ;
Sun, Franklin ;
Brodsky, Marina ;
Guan, Zhonghong .
EUROPEAN UROLOGY, 2009, 56 (03) :534-541
[6]   Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe [J].
Chapple, Christopher R. ;
Montorsi, Francesco ;
Tammela, Teuvo L. J. ;
Wirth, Manfred ;
Koldewijn, Evert ;
Fernandez Fernandez, Eldiberto .
EUROPEAN UROLOGY, 2011, 59 (03) :342-352
[7]   A 12-WEEK PLACEBO-CONTROLLED STUDY OF PRAZOSIN IN THE TREATMENT OF PROSTATIC OBSTRUCTION [J].
CHAPPLE, CR ;
CHRISTMAS, TJ ;
MILROY, EJG .
UROLOGIA INTERNATIONALIS, 1990, 45 :47-55
[8]   A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder [J].
Chapple, CR ;
Roehrborn, CG .
EUROPEAN UROLOGY, 2006, 49 (04) :651-659
[9]   Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):: Efficacy and tolerability in a placebo and active comparator controlled phase 3a study [J].
Chapple, CR ;
Al-Shukri, SH ;
Gattegno, B ;
Holmes, S ;
Martínez-Sagarra, JM ;
Scarpa, RM ;
Trip, OBV ;
Vik, V ;
van der Putten-Slob, I .
EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :33-44
[10]   The total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management: Introduction and conclusions [J].
Chapple, CR .
EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (07) :1-5